Back to News
Market Impact: 0.28
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
TG Therapeutics said its multiple sclerosis therapy BRIUMVI has captured more than one-third of the intravenous anti-CD20 market and continues to gain share approaching its fourth full year on the market. The market-share momentum supports a favorable commercial trajectory for the company’s key drug franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
TGTX0.72
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead